These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 25773849)

  • 1. Importance of PET/CT scan use in planning radiation therapy for lymphoma.
    Milana MA; Marko E; Miroslav L; Tihomir D
    Asian Pac J Cancer Prev; 2015; 16(5):2051-4. PubMed ID: 25773849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study.
    Weber DC; Peguret N; Dipasquale G; Cozzi L
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1578-86. PubMed ID: 19596171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG).
    Specht L; Yahalom J; Illidge T; Berthelsen AK; Constine LS; Eich HT; Girinsky T; Hoppe RT; Mauch P; Mikhaeel NG; Ng A;
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):854-62. PubMed ID: 23790512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size.
    Campbell BA; Voss N; Pickles T; Morris J; Gascoyne RD; Savage KJ; Connors JM
    J Clin Oncol; 2008 Nov; 26(32):5170-4. PubMed ID: 18838714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients.
    Weber DC; Johanson S; Peguret N; Cozzi L; Olsen DR
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):490-7. PubMed ID: 20800383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involved-nodal radiation therapy leads to lower doses to critical organs-at-risk compared to involved-field radiation therapy.
    Mulvihill DJ; McMichael K; Goyal S; Drachtman R; Weiss A; Khan AJ
    Radiother Oncol; 2014 Aug; 112(2):279-83. PubMed ID: 25082095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy.
    Koeck J; Abo-Madyan Y; Lohr F; Stieler F; Kriz J; Mueller RP; Wenz F; Eich HT
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):268-76. PubMed ID: 22079733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transformation in the use of radiation therapy of Hodgkin lymphoma: new concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT).
    Yahalom J
    Eur J Haematol Suppl; 2005 Jul; (66):90-7. PubMed ID: 16007875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy.
    Chera BS; Rodriguez C; Morris CG; Louis D; Yeung D; Li Z; Mendenhall NP
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1173-80. PubMed ID: 19386423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy.
    Campbell BA; Hornby C; Cunninghame J; Burns M; MacManus M; Ryan G; Lau E; Seymour JF; Wirth A
    Ann Oncol; 2012 May; 23(5):1259-1266. PubMed ID: 21980193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does Radiation Have a Role in Advanced Stage Hodgkin's or Non-Hodgkin Lymphoma?
    Specht L
    Curr Treat Options Oncol; 2016 Jan; 17(1):4. PubMed ID: 26739151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma.
    Maraldo MV; Brodin NP; Aznar MC; Vogelius IR; Munck af Rosenschöld P; Petersen PM; Specht L
    Ann Oncol; 2013 Aug; 24(8):2113-8. PubMed ID: 23619032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation therapy planning for early-stage Hodgkin lymphoma: experience of the International Lymphoma Radiation Oncology Group.
    Maraldo MV; Dabaja BS; Filippi AR; Illidge T; Tsang R; Ricardi U; Petersen PM; Schut DA; Garcia J; Headley J; Parent A; Guibord B; Ragona R; Specht L
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):144-52. PubMed ID: 25670544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
    Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study.
    Hoppe BS; Flampouri S; Su Z; Morris CG; Latif N; Dang NH; Lynch J; Li Z; Mendenhall NP
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):260-7. PubMed ID: 22014950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interobserver delineation uncertainty in involved-node radiation therapy (INRT) for early-stage Hodgkin lymphoma: on behalf of the Radiotherapy Committee of the EORTC lymphoma group.
    Aznar MC; Girinsky T; Berthelsen AK; Aleman B; Beijert M; Hutchings M; Lievens Y; Meijnders P; Meidahl Petersen P; Schut D; Maraldo MV; van der Maazen R; Specht L
    Acta Oncol; 2017 Apr; 56(4):608-613. PubMed ID: 28105886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of passive-beam proton therapy, helical tomotherapy and 3D conformal radiation therapy in Hodgkin's lymphoma female patients receiving involved-field or involved site radiation therapy.
    Horn S; Fournier-Bidoz N; Pernin V; Peurien D; Vaillant M; Dendale R; Fourquet A; Kirova YM
    Cancer Radiother; 2016 Apr; 20(2):98-103. PubMed ID: 26992750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doses to carotid arteries after modern radiation therapy for Hodgkin lymphoma: is stroke still a late effect of treatment?
    Maraldo MV; Brodin P; Aznar MC; Vogelius IR; Munck af Rosenschöld P; Petersen PM; Specht L
    Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):297-303. PubMed ID: 23910709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes?
    Girinsky T; Pichenot C; Beaudre A; Ghalibafian M; Lefkopoulos D
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):218-26. PubMed ID: 16169675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations for the use of radiotherapy in nodal lymphoma.
    Hoskin PJ; Díez P; Williams M; Lucraft H; Bayne M;
    Clin Oncol (R Coll Radiol); 2013 Jan; 25(1):49-58. PubMed ID: 22889569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.